The added value Outcome Capital was responsible for was 10 times greater then the value we invested in their services. Our only regret was in not bringing them on sooner.
The Outcome team got fully up to speed with all aspects of our technology and business, and could pitch our company’s story, and value proposition, as well as anyone. They researched a full list of potential acquirers in order to target those with high potential, and articulate the true value proposition for each target in very clear terms.
I was impressed by Outcome Capital’s thoughtful M&A strategy and process, which stemmed from their ability to capture the complexities of Beryllium’s scientific and business value propositions.
I have worked with Outcome Capital for multiple, complex transaction. They bring operational experience to the table like no other investment bankers I have ever worked with.
Outcome Capital looks forward to attending JP Morgan’s Annual Healthcare Conference in January 2018. If you are interested in meeting to discuss your M&A and capital needs, please connect with one of us to arrange a time. Oded Ben-Joseph, Ph.D., MBA, Biotech & Medical Devices Arnie Freedman, Medical Devices & Healthcare Services Shawn […]Read More
Outcome Capital Announces UCB Pharma Has Acquired Beryllium Discovery June 6, 2017, Boston, MA. Outcome Capital, an investment banking firm that serves middle market growth companies in the life science and technology segments, today announced that UCB Pharma, Ltd. has acquired privately held Beryllium Discovery, LLC. Beryllium, a specialized drug discovery contract research organization (CRO), […]Read More